These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 16298225)

  • 1. Deregulating the pharmacy market: the case of Iceland and Norway.
    Anell A
    Health Policy; 2005 Dec; 75(1):9-17. PubMed ID: 16298225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementing competition in the pharmacy sector: lessons from Iceland and Norway.
    Anell A; Hjelmgren J
    Appl Health Econ Health Policy; 2002; 1(3):149-56. PubMed ID: 14619266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Entry of new pharmacies in the deregulated Norwegian pharmaceuticals market--consequences for costs and availability.
    Rudholm N
    Health Policy; 2008 Aug; 87(2):258-63. PubMed ID: 18164509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Competition among pharmacies and the typology of services delivered: The Portuguese case.
    Martins L; Queirós S
    Health Policy; 2015 May; 119(5):640-7. PubMed ID: 25812747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pricing behaviour of pharmacies after market deregulation for OTC drugs: the case of Germany.
    Stargardt T; Schreyögg J; Busse R
    Health Policy; 2007 Nov; 84(1):30-8. PubMed ID: 17553587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Price regulation and generic competition in the pharmaceutical market.
    Dalen DM; Strøm S; Haabeth T
    Eur J Health Econ; 2006 Sep; 7(3):208-14. PubMed ID: 16841230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do online pharmacies fit European internal markets?
    Mäkinen MM; Rautava PT; Forsström JJ
    Health Policy; 2005 May; 72(2):245-52. PubMed ID: 15802158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse pharmaceutical payment incentives and providers' behaviour: the emergence of GP-owned gateway pharmacies in Taiwan.
    Lee YC; Huang KH; Huang YT
    Health Policy Plan; 2007 Nov; 22(6):427-35. PubMed ID: 17901065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multimethod research into policy changes in the pharmacy sector--the Nordic case.
    Almarsdóttir AB; Traulsen JM
    Res Social Adm Pharm; 2009 Mar; 5(1):82-90. PubMed ID: 19285293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of pharmacy market deregulation regarding patient-centred drug care in Germany from a health economics perspecitve].
    Rumm R; Böcking W
    Dtsch Med Wochenschr; 2013 Mar; 138(9):441-4. PubMed ID: 23423941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Entry and competition of retail pharmacies: A case study of OTC drugs sales and ownership deregulation1.
    Bilka M; Duarte AP; Lábaj M
    Ceska Slov Farm; 2023; 72(1):11-20. PubMed ID: 36858976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of local competition on the willingness of community pharmacies to supply medication therapy management services.
    Brooks JM; Klepser DG; Urmie JM; Farris KB; Doucette WR
    J Health Hum Serv Adm; 2007; 30(1):4-27. PubMed ID: 17557694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmaceutical care in community pharmacies: practice and research in Sweden.
    Westerlund LT; Björk HT
    Ann Pharmacother; 2006 Jun; 40(6):1162-9. PubMed ID: 16735653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmaceutical care in community pharmacies: practice and research in Estonia.
    Volmer D; Vendla K; Vetka A; Bell JS; Hamilton D
    Ann Pharmacother; 2008 Jul; 42(7):1104-11. PubMed ID: 18577761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Policies encouraging price competition in the generic drug market: Lessons from the European experience].
    Puig-Junoy J
    Gac Sanit; 2010; 24(3):193-9. PubMed ID: 20189690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liberalization and integration of drug distribution in the EU 28 and Norway.
    Písek J; Pícha K
    Ceska Slov Farm; 2018; 67(1):14-24. PubMed ID: 30157663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlled substances in long-term care pharmacy: part 2.
    Martin CM
    Consult Pharm; 2008 Oct; 23(10):742-56. PubMed ID: 19032014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 2017 deregulation of pharmacies in Italy: Introducing non-pharmacist ownership.
    Gallone EL; Ravetto Enri L; Pignata I; Baratta F; Brusa P
    Health Policy; 2020 Dec; 124(12):1281-1286. PubMed ID: 32994057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacy discounts on generic medicines in France: is there room for further efficiency savings?
    Kanavos P; Taylor D
    Curr Med Res Opin; 2007 Oct; 23(10):2467-76. PubMed ID: 17764613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Horizontal and vertical concentrations in the evolution of hospital competition.
    Starkweather DB; Carman JM
    Adv Health Econ Health Serv Res; 1987; 7():179-94. PubMed ID: 10291980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.